Anthrax dispute suggests Bioshield woes
(AP)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/ap/20061001/ap_on_he_me/project_bioshield_dispute"><img src="http://d.yimg.com/us.yimg.com/p/ap/20061001/capt.a50446192f884c71baf1779ca605762b.project_bioshield_dispute_fx111.jpg?x=130&y=89&sig=n25nzg4wsOA_J6W.vAYYjg--" align="left" height="89" width="130" alt="Jonah Jacobson, a VaxGen lab technician, holds a syringe of anthrax vaccine at the VaxGen laboratory in South San Francisco, Calif., Thursday, Sept. 21, 2006. Five years after anthrax attacks left five dead, sickened 17 and terrified America, millions of vaccine shots developed through cutting-edge genetic engineering were supposed to be filling a new national stockpile of biodefense drugs. (AP Photo/Benjamin Sklar)" border="0" /></a>AP - By now, millions of anthrax vaccine shots developed through cutting-edge genetic engineering were supposed to be filling a new national stockpile of biodefense drugs.</p><br clear="all"/>